Zhang X, Miao X, Tan W, et al. Identification of functional genetic variants in Cyclooxygenase-2 and their association with risk of esophageal cancer[J]. Gastroenterol, 2005, 129: 565-576.
[3]
Zheng J, Chen S, Jiang L, et al. Functional genetic variations of cyclooxygenase-2 and susceptibility to acute myeloid leukemia in a chinese population[J]. Eur J Haematol, 2011, 87: 486-493.
[4]
Chiang SL,Chen PH, Lee CH, et al. Up-regulation of inflammatory signalings by areca nut extract and role of cyclooxygenase-2-1195G>A polymorphism reveal risk of oral cancer[J]. Cancer Res,2008,68:8489-8498.
[5]
Naoyuki Ueda, Yoshihiko Maehara, Osamu Tajima, et al. Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: the self defense forces health study[J]. Cancer Sci, 2008, 99: 576-581.
[6]
Gangwar R, Mandhani A, Mittal RD. Functional polymorphisms of cyclooxygenase-2(COX-2)gene and risk for urinary bladder cancer in North India[J]. Surgery, 2011, 149: 126-134.
[7]
J Shi, NL Misso, MA Kedda, et al. Cyclooxygenase-2 gene polymorphisms in an Australian population: association of the -1195G>A promoter polymorphism with mild asthma[J]. Clin and Exp Allergy, 2008, 38: 913-920.
C and -1195A-->G and colorectal cancer risk[J]. World J Gastroenterol, 2009, 15: 4561-4565. -->
[8]
Hoff JH, te Morsche RH, Roelofs HM, et al. COX-2 polymorphisms -765G-->C and -1195A-->G and colorectal cancer risk[J]. World J Gastroenterol, 2009, 15: 4561-4565.
[9]
Peters WH, Lacko M, Te Morsche RH, et al. COX-2 polymorphisms and the risk for head and neck cancer in white patients[J]. Head Neck, 2009, 31: 938-943.
[10]
Vogel U, Christensen J,Wallin H, et al. polymorphisms in COX-2, NSAID use and risk of basal cell carainoma in a prospective study of Danes[J]. Mutat Res, 2007, 617: 138-146.
[11]
Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights[J]. Lipid Res, 2009, 50: S29-S34.
[12]
Murat N, Hocaoglu N, Karatosun V, et al. The effects of non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs on heterotopic ossification in rats[J]. Med Sci Monit, 2005, 11: BR449-BR451.
[13]
Minghetti L. Cyclooxygenase-2(COX-2)in inflammatory and degenerative brain disease[J]. Neuropathol Exp Neurol, 2004, 63: 901-910.
[14]
Chakraborti AK, Garg SK, Kumar R, et al. Progress in COX-2 Inhibitors: a journey so far[J]. Curr Med Chem, 2010, 17: 1563-1593.
[15]
Danforth KN, Hayes RB, Rodriguez C, et al. Polymorphic variants in PTGS2 and prostate cander risk: results from two large nested case-control studies[J]. Carcinogenesis, 2008, 29: 568-572.
[16]
Pereira C, Pimentel-Nunes P, Brandao C, et al. COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention[J]. Eur J Gastroenterol. Hepatol, 2010, 22: 607-613.
[17]
Hoeft B, Becker N, Deeg E, et al. Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory gene and risk of lymphoma[J]. Cancer Causes Control, 2008,19: 163-173.
[18]
Cheng L, Liu X, Plummer SJ, et al. COX-2 genetic variation, NSAIDs, and advanced prostate cancer risk[J]. Br J Cancer, 2007, 97: 557-561.
